Not necessarily speaking directly, but I think it's important for the committee to recognize that the common drug review process doesn't differentiate drugs based on their country of origin. In fact, that information is sometimes very difficult for us to know.
Recently, I found out that Vioxx was a drug that was discovered in Canada. But I would have been quite disheartened if it were treated differently from the rest of the drugs because it was discovered in Canada.
So we take a very objective view. Our feeling is that if drugs are discovered in Canada, they still need to meet the same standards of evidence to ensure that they are still safe and effective and are competitive and are worthwhile investments for taxpayers, not from an R and D perspective but from a health perspective.